ArticlePLOS global public health2025
A cluster randomised controlled trial of community groups using Participatory Learning and Action to prevent and control diabetes and intermediate hyperglycaemia in rural Bangladesh.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Asia at the Epicenter of the Global Cardiometabolic Shift.JACC. Asia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community mobilisation through Participatory Learning and Action (PLA) has been shown to be effective for a range of health outcomes, including diabetes. Using a cluster randomised controlled trial we evaluated the impact of a PLA community mobilisation intervention for diabetes prevention and control when implemented in rural Bangladesh in 2021-2022 and adapted to the evolving context of the COVID-19 pandemic. 108 PLA groups held a minimum of 13 meetings over a total implementation period of 20 months. Random cross-sectional samples of adults (aged ≥30 years) at baseline (pre-intervention, n = 1392) and at endline (post-intervention, n = 1343) were selected to evaluate intervention impact on the primary outcome of prevalence of intermediate hyperglycaemia and diabetes assessed through fasting blood glucose concentrations and two-hour oral glucose tolerance tests. Secondary outcomes included blood pressure, knowledge of diabetes, and behavioural outcomes, including diet, physical activity, and care-seeking. Results showed no evidence of an intervention effect on prevalence of intermediate hyperglycaemia and diabetes between study arms (adjusted difference -1.19% (95% CI -10.74, 8.36), p = 0.784). Large increases in diabetes knowledge were recorded and the intervention was associated with a significant reduction in mean diastolic blood pressure (-2.98 (-5.55, -0.41), p = 0.028) and possible reductions in the prevalence of hypertension (-7.40% (-16.03, 1.24), p = 0.0845) and abdominal obesity (-15.23% (-33.02, 2.56), p = 0.085). Although COVID-related interruptions and adaptations to implementation of PLA may have impacted effectiveness, the PLA approach to non-communicable disease prevention and control continues to show promise in resource-poor settings. Trial registration: ISRCTN42219712 - registered 31st October 2019. Status: complete.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.